Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients

Completed

• Conditions: Neuropathic Pain; Pain; Upper GI Cancer; Depression; Quality of Life

• Registration Number: NCT01718821
• Lead Sponsor: National Cheng Kung University

Brief Summary

Pain is one of the most common symptoms associated with cancer. The approach to pain management compresses routine pain assessments, utilizes both pharmacologic and nonpharmacologic interventions, and requires ongoing reevaluation of the patient. Cancer pain can be well controlled in the vast majority of patients if the algorithms of pain control are systematically applied, carefully monitored, and tailored to the needs of the individual patient.This study is aimed to assess the current pain managements in upper gastrointestinal cancer patients in Taiwan. The effects of neuropathic pain and depression on the enrolled patients would also be assessed.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-09
• Study First Submitted: 2012-10-16
• Study First Submitted QC: 2012-10-28
• Study First Posted: 2012-10-31
• Primary Completion: 2013-09
• Status Verified: 2014-09
• Study Completion: 2014-09
• Last Update Submitted: 2014-09-24
• Last Update Posted: 2014-09-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• with a diagnose of advanced upper GI cancer based on pathology or imaging studies
• could report pain intensities and answer questionnaires by him/herself

Exclusion Criteria

• with major neurologic or psychiatric diseases
• could not report pain intensities and answer questionnaires by him/herself

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pain, assessed by BPI-SF.	Assessed at enrolled date (Day 1)	Pain intensities of participants would be assessed by BPI-SF at D1.
Changes in pain, assessed by BPI-SF.	Baseline and 1 month.	Changes in pain intensities of participants would be assessed by BPI-SF. The changes in pain would be assessed again after 1 month when participants have outpatient visits or during their admission. An expected following duration average of would be 4 weeks.

Secondary Outcome Measures

Name	Time	Method
Depression, assessed by two stem questions.	Assessed at enrolled date (Day 1)	Depression of participants would be assessed by questionnaires as mentioned at D1.
Changes in depression, assessed by two stem questions.	Baseline and 1 month.	Changes in depression status would be assessed by questionnaires as mentioned. The changes would be assessed again after 1 month when participants have outpatient visits or during their admission. An expected following duration average of would be 4 weeks.
Quality of life, assessed by EROTC QLQ C30.	Day 1	Quality of life of participants would be assessed by questionnaires as mentioned at D1.
Neuropathic pain, assessed by DN4 questions.	Day 1	Neuropathic pain of participants would be assessed by questionnaires as mentioned at D1.
Changes in quality of life. Quality of life, assessed by EROTC QLQ C30.	Baseline and 1 month.	Changes in quality of life would be assessed by questionnaires as mentioned. The changes would be assessed again after 1 month when participants have outpatient visits or during their admission. An expected following duration average of would be 4 weeks.
Changes in neuropathic pain. Neuropathic pain, assessed by DN4 questions.	Baseline and 1 month.	Changes in neuropathic pain would be assessed by questionnaires as mentioned. The changes would be assessed again after 1 month when participants have outpatient visits or during their admission. An expected following duration average of would be 4 weeks.

Trial Locations

Locations (1)

National Cheng Kung University Hospital; 🇨🇳 Tainan, Taiwan